RNA, U6 small nuclear 823, pseudogene (RNU6-823P)

RNU6-823P is annotated as a pseudogene derived from the U6 small nuclear RNA gene family[2][5]. U6 small nuclear RNA (snRNA) is a highly conserved component of the spliceosome, essential for pre-mRNA splicing in eukaryotes[1][3]. However, RNU6-823P specifically refers to a pseudogene copy—a DNA sequence that resembles the functional U6 snRNA gene but is generally considered nonfunctional and does not produce an active snRNA product[5]. Pseudogenes like RNU6-823P do not encode proteins and are not recognized as therapeutic or pharmacological targets. They can sometimes be transcribed into noncoding RNAs with regulatory or decoy functions (such as acting as competitive endogenous RNAs or affecting microRNA pathways), but there is no evidence in the search results that RNU6-823P specifically has such functions[4]. Pseudogenes have been implicated in a range of potential disease processes, usually through indirect genomic effects like gene conversion, or by serving as regulators of gene expression, but the evidence for any role for RNU6-823P in disease is lacking, and no direct associations or drug interactions are reported for this entity[6]. Key points: - RNU6-823P is a pseudogene, not a protein-coding gene or a traditional therapeutic target[2][5]. - It is named and annotated as a pseudogene of U6 small nuclear RNA, part of a large family of similar pseudogenes found in vertebrate genomes[3]. - No evidence indicates functional, druggable, or biomarker status, or known disease involvement for RNU6-823P specifically. - Given the lack of gene product and the absence of functional validation, it should not be classified as a pharmacological or therapeutic target. If structured as canonical information, most fields would be null except for its identity as a pseudogene; additionally, “is_incorrect” is true because it is not a direct drug or therapeutic target.

Other names

RNU6-823P